Sandoz Group AG (VIE:SDZ)
Austria · Delayed Price · Currency is EUR | Market Cap | 33.72B +62.4% |
| Revenue (ttm) | 10.22B +10.3% |
| Net Income | 565.44M +184.6% |
| EPS | 1.29 +180.8% |
| Shares Out | n/a |
| PE Ratio | 59.64 |
| Forward PE | 20.48 |
| Dividend | 0.86 (1.18%) |
| Ex-Dividend Date | Apr 13, 2026 |
| Volume | n/a |
| Open | 76.44 |
| Previous Close | 75.14 |
| Day's Range | 76.44 - 77.28 |
| 52-Week Range | 52.52 - 80.82 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
News
Swiss Market Ends Moderately Higher; Sandoz Group Jumps Over 6%
(RTTNews) - Despite very nearly falling below the flat line a little past noon, the Switzerland stock market stayed positive right through the trading session on Wednesday thanks to selective buying a...
Sandoz Group AG (SDZNY) Reports Solid H1 Sales Growth Amid Mixed Valuation Signals
Sandoz Group AG (SDZNY) Reports Solid H1 Sales Growth Amid Mixed Valuation Signals
Sandoz Shares Climb After Biosimilar Sales Drive Growth
Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a return to growth in generics.
Sandoz Posts Strong H1 2026 Results With Biosimilars Driving Growth; Stock-Up
(RTTNews) - Sandoz Group AG (SDZNY) reported financial results for the first half of 2026, showing double-digit growth in biosimilars and steady expansion in generics. The Basel-based company reaffirm...
Sandoz Group AG Earnings Call Transcript: Q2 2026
Strong H1 2026 results driven by biosimilars and new launches led to 5% net sales growth and 15% core EBITDA increase. Guidance for 2026 is reaffirmed, with robust pipeline expansion, regulatory milestones, and major US litigation resolved, supporting confidence in future growth.
Sandoz Group AG Slides: Q2 2026
Sandoz Group AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Sandoz Group AG Quarterly report: Q2 2026
Sandoz Group AG has published its Q2 2026 quarterly earnings report on August 5, 2026.
Sandoz Group AG Earnings release: Q2 2026
Sandoz Group AG released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Sandoz results narrowly beat sales expectations
Swiss generic maker Sandoz reported a 9% jump in second quarter net sales on Wednesday, slightly above analyst expectations, as it reaped the benefits of patent expirations in its biosimila...
Sandoz takes steps to resolve U.S. generic medicine pricing litigation
Sandoz (SDZNY) announces several steps to further resolve the US Generic Drug Antitrust Pricing Litigation. Sandoz and its subsidiary Fougera Pharmaceuticals have entered into a settlement agreement t...
Sandoz to Pay Around $480 Million to Settle U.S. Antitrust Pricing Litigations
The agreements mean the remaining claims against the Swiss maker of generic drugs in the U.S. generic antitrust litigation are those from individual plaintiffs.
Sandoz To Pay $450 Mln To Settle U.S. Generic Drug Litigation; Backs FY26 Outlook
(RTTNews) - Sandoz Group AG (SDZNY, SDZ.SW), a Swiss company that focuses on generic pharmaceuticals and biosimilars, on Monday reached settlement agreements with 43 US states and territories and indi...
Sandoz agrees $450 mln settlement with 43 US states over antitrust claims
Swiss generic drugmaker Sandoz said on Monday that it has entered into a $450 million settlement agreement with 43 U.S. states and territories to resolve litigations concerning alleged anti-compet...
Sandoz Secures Brazil Approval For New Semaglutide Treatment Option
(RTTNews) - Sandoz Group AG (SDZNY) a company focused on affordable medicine, announced that Brazil's health regulator ANVISA has granted marketing authorization for Owozy (semaglutide), a new treatme...
Generic drug sector seeks policy fixes after Trump tariff threat
The generic drug market still faces structural and purchasing hurdles despite strong U.S. growth, an industry group noted on Wednesday, after President Donald Trump said imported generic medicines w...
Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2%
Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2%
Generic drugmaker Sandoz to engage with US after Trump tariff threat
Swiss generic drugmaker Sandoz said on Wednesday it would continue discussions with policymakers after U.S. President Donald Trump threatened the industry with steep tariffs unless drugmakers manufa...
Europe optimized its supply chains for cost. Now it must pay for resilience
Richard Saynor, CEO of Fortune 500 Europe company, Sandoz Group, and manufacturer of generic medicines, argues resilience requires investment that markets often fail to reward
Sandoz announces U.S. FDA accepted for review two ANDAs for tirzepatide
Sandoz (SDZNY) announces that the US Food and Drug Administration, FDA, has accepted for review two Abbreviated New Drug Applications, ANDAs, for generic versions of tirzepatide. The ANDAs seek approv...
FDA set to review Sandoz's generic GLP-1s
The U.S. Food and Drug Administration has agreed to review Swiss generics drugmaker Sandoz's two generic tirzepatide GLP-1s that, if approved, would rival obesity drugs made by Eli Lilly.
Generic drugmaker Sandoz files anti-dumping complaint about Chinese antibiotics imports
Swiss generic drugmaker Sandoz filed a draft anti-dumping complaint with the European Commission over Chinese imports of the antibiotic ingredient amoxicillin, part of the penicillin family, the co...
Sandoz confirms the EC granted marketing authorization for Bysumlog, Dazparda
Sandoz (SDZNY) confirms that the European Commission, EC, has granted marketing authorization for Bysumlog and Dazparda. The two biosimilar insulins, for injection in prefilled pens, are developed by ...
Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Sandoz upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Sandoz (SDZNY) to Overweight from Equal Weight with an unchanged price target of CHF 75. The firm finds the stock’s valuation “compelling” given Sandoz’s accelerating sales growth th...
Sandoz price target lowered to CHF 65 from CHF 70 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Sandoz (SDZNY) to CHF 65 from CHF 70 and keeps a Hold rating on the shares.